Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Blopress

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Blopress was produced by Takeda.

Takeda CEO admits to Blopress mis-marketing

Takeda CEO admits to Blopress mis-marketing

Hasegawa told the Wall Street Journal that the company had used a graph in promotional literature indicating Blopress (candesartan cilexetil) was more effective than rival blood pressure drug Norvasc (amlodipine) from ... Blopress - also sold as Atacand -

Takeda rides out Actos decline as fiscal 2012 sales rise

Takeda rides out Actos decline as fiscal 2012 sales rise steep decline for antihypertensive Blopress (candesartan), also on generic competition, which ended the year down 22 per cent to 169bn yen. ... The drug's US launch is due in the summer. Azilva also contributed to Takeda's domestic sales growth on the

Country report: The healthcare market in Japan

Country report: The healthcare market in Japan Aricept. donepezil. Eisai. Alzheimer's disease. 2. Blopress. candesartan. Takeda. Hypertension. 3.

EU approval for Takeda's once-daily hypertension drug Edarbi

Takeda's own candesartan cilexetil (marketed as Amias and Blopress in Europe), which made $2.8bn last year.

A rush for sweet success

DysportTM (Medicis). Glabellar lines. US. Candesartan cilexetil/hydrochlorothiazide. Blopress Plus (Takeda). Essential hypertension.

1 2 3 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics